Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab.
Viktoria StühlerLisa HerrmannSteffen RauschArnulf StenzlJens BedkePublished in: Cancers (2022)
SII is both prognostic and predictive and could refine decision making in patients with unclear imaging on therapy with ipilimumab plus nivolumab.